TORONTO–( BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has selected Alcohol Use Disorder (“AUD”) as the initial target indication for its proprietary deuterated psychedelic tryptamine, CYB003. AUD is a chronic relapsing brain disorder characterized by an impaired…
